Revolution Medicines
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering novel, targeted medicines for patients living with cancer.
www.revmed.comHere are the latest public-availability updates on Revolution Medicines, based on recent press and news coverage.
-
Key development: Daraxonrasib, a KRAS-targeting inhibitor from Revolution Medicines, has generated attention for potential pancreatic cancer therapy. Early-stage data suggest meaningful activity and ongoing consideration by regulators; readers have seen mentions of FDA-related steps and early access programs in 2026 coverage. This is reflected in multiple outlets noting trial progress and regulatory interest.[1][3][4][9]
-
Regulatory and clinical milestones: Reports in 2024–2025 highlighted Phase 1/1b and Phase 3 efforts around RMC-6236 and related RAS-directed programs, with references to orphan drug designations and expedited review considerations in some markets. News summaries also describe partnerships and financings intended to support expanded development of the RAS(ON) portfolio.[2][3][5][6]
-
Market activity and coverage: Financial press and market trackers reported stock movement tied to regulatory milestones, trial readouts, and strategic funding deals related to Revolution Medicines’ pipeline, including collaborations and potential catalysts for late-stage milestones. This includes coverage of share price reactions around regulatory/designation news and trial updates.[3][4][5]
-
Public-facing information: The company’s own site reiterates its mission to develop targeted cancer medicines, with emphasis on its KRAS-targeted programs and pipeline progression. Company communications typically accompany third-party coverage with details on program objectives and upcoming milestones.[6]
Illustration example
- Timeline snapshot (high level):
- 2024–2025: Phase 1/1b updates and early regulatory designations for RAS-targeted therapies.
- 2025: Financing and collaboration announcements to support RAS pipeline expansion.
- 2026: Ongoing trial updates and regulatory interactions around daraxonrasib/RMC-6236 and related molecules.
If you’d like, I can:
- Pull the most recent specific press release dates and summarize them.
- Create a short timeline table of key milestones with sources.
- Track a particular program (e.g., daraxonrasib vs. RMC-6236) and compare reported efficacy signals and safety profiles from the latest trials.